Background: The activating point mutation v-Raf murine sarcoma viraloncogene homolog B1 (BRAFV600E), is the most common and specificgenetic alteration in papillary thyroid carcinoma (PTC) with a prevalence of29-83%. The mutation causes a change in amino acid at position 600 fromvaline to glutamic acid in the BRAF protein kinase, resulting in aberrantactivation of the mitogen- activated protein MAP kinase signaling pathway.Studies have shown a strong association of BRAFV600E mutation withaggressive clinicopathological outcomes of PTC and therefore this mutationwas viewed as a strong prognostic molecular marker for poorer prognosis ofPTC.Objectives: The aim of the study was to investigate the frequency of theBRAFV600E mutation among the Egyptian patients with PTC and tocorrelate with the clinicopathological status of the patients.Subjects and Methods: The study included fifty formalin fixed paraffinembedded (FFPE) thyroid tumor tissue samples collected from thedepartment of surgical pathology from both Faculty of medicine, Cairouniversity and National cancer institute. Patients Data archived from patientsrecords included age, sex, multifocality, vascular invasion, lymph nodemetastasis and distant metastasis. Tissue samples were tested for themutation by polymerase chain reaction-restriction fragment lengthpolymorphism (PCR-RFLP) and direct DNA sequencing.Results: One (2%) out of the 50 FFPE tumor tissue samples was found tobe heterogeneous positive for the BRAFV600E mutation. DNA sequencingresults demonstrated confirmation of the results.Conclusion: The BRAFV600E is not common among Egyptian patientswith PTC.